Matthias Will
Chief Development Officer (Cdo) Autolus
Seminars
Wednesday 16th September 2026
Evolving CAR-T Therapies to Shift Beyond Hematological Malignancies
12:10 pm
- Comparing PK profiles in autoimmune diseases and hematological malignancies to uncover differences in exposure, persistence, and dosing strategies
- Highlighting how endpoints, patient selection, and lymphodepletion approaches differ in lupus and MS
- Exploring clinical safety data to enhance autologous CAR-T expansions beyond oncology
